Switching of biologics in RA patients who do not respond to the first biologic.
(2018) Joint Bone Spine — Vol. 85, n° 4, p. 395-397 (2018)
Files
2018_Durez_Joint_Bone_Spine.pdf
Restricted Access - Adobe PDF
- 506.16 KB
Details
- Authors
- Abstract
- INTRODUCTION : In the past 20 years, there has been extraordinary progress in rheumatology in terms of the understanding of the pathophysiological mechanisms of rheumatoid arthritis (RA) with, as a result, the advent of targeted treatments using biologics. These maintenance treatments, which are referred to as BioDMARDs have a substantial capacity to control the symptoms, to reduce the inflammation, to induce clinical remission, to prevent functional disability, and to protect against joint destruction. BioDMARDs can only be administered in outpatient clinics as treatments of secondary intention, after failure of a conventional maintenance treatment such as Methotrexate (MTX). Eleven BioDMARDs have been approved for RA in case of an insufficient response to MTX, five of which are TNF inhibitors (Etanercept, Infliximab, Adalimumab, Certolizumab, Golimumab, and, more recently, biosimilars of Infliximab and of Etanercept). Tocilizumab is an inhibitor of Interleukin-6, Abatacept is an immunomodulator of T lymphocytes, and Rituximab is an inhibitor of B lymphocytes [1]. [N...]
- Affiliations
Citations
Durez, P. (2018). Switching of biologics in RA patients who do not respond to the first biologic. Joint Bone Spine, 85(4), 395-397. https://doi.org/10.1016/j.jbspin.2018.02.001 (Original work published 2018)